Session

Novel biomarkers for prostate cancer prediction

Poster Session 31

  • Location:
    Room Madrid (Hall B2, level 0)
  • Chairs:
     P-A. Abrahamsson, Malmö (SE)
     P. Cornford, Liverpool (GB)
     N. Suardi, Milan (IT)
  • Aims and objectives of this session

    The session focuses on performance characteristics of novel biomarkers and multivariable models to predict prostate cancer and its grading

  • Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.
* 380
Novel long non-protein coding RNAs as biomarkers and potential therapeutic targets for prostate cancer

By: Christ-Breulmann S.1, Horn F.2, Puppel S-H.1, Buschmann T.1, Reiche K.1, Specht M.1, Bertram C.1, Friedrich M.1, Blumert C.1, Binder S.1, Hackermüller J.3, Kreuz M.4, Löffler M.4, Toma M.I.5, Muders M.5, Baretton G.B.5, Fröhner M.6, Füssel S.6, Wirth M.6

Institutes: 1Fraunhofer Institute for Cell Therapy and Immunology, Dept. of Diagnostics, Leipzig, Germany, 2University of Leipzig, Institute of Clinical Immunology, Leipzig, Germany, 3Helmholtz Centre for Environmental Research, Young Investigator Group Bioinformatics & Transcriptomics, Leipzig, Germany, 4University of Leipzig, Institute for Medical Informatics, Statistics and Epidemiology, Leipzig, Germany, 5University Hospital “Carl Gustav Carus”, Technical University Dresden, Institute of Pathology, Dresden, Germany, 6University Hospital “Carl Gustav Carus”, Technical University Dresden, Dept. of Urology, Dresden, Germany

381
The 4Kscore predicts the grade and stage of prostate cancer in the radical prostatectomy specimen: Results from a multi-institutional prospective trial

By: Punnen S.1, Nahar B.1, Pavan N.1, Sjoberg D.2, Zappala S.3, Parekh D.1

Institutes: 1University of Miami Miller School of Medicine, Dept. of Urology, Miami, United States of America, 2Memorial Sloan Kettering Cancer Center, Dept. of Urology, New York, United States of America, 3Andover Urology, Dept. of Urology, Andover, United States of America

382
The 4kscore® test is comparable to biopsy in accurately predicting high-grade cancer in radical prostatectomy specimens with potential implications for active surveillance

By: Alcaraz A.1, Newmark J.2, Casariego J.3, Dong Y.2, Sant G.2, Mathur M.2, Steiner M.2

Institutes: 1Hospital Clinic, Dept. of Urology, Barcelona, Spain, 2OPKO Health, Inc., Dept. of Medical Affairs and Diagnostics, Miami, United States of America, 3OPKO Health Europe, Dept. of Medical, Barcelona, Spain

383
Multicenter validation study of a urine-based molecular biomarker algorithm to predict high-grade prostate cancer

By: Hendriks R.J.1, Dijkstra S.1, Trooskens G.9, Van Criekinge W.9, Cornel E.B.2, Jannink S.A.3, De Jong H.3, Hessels D.3, Smit F.P.3, Melchers W.J.G.1, Leyten G.H.J.M.1, De Reijke T.M.4, Vergunst H.5, Kil P.6, Knipscheer B.C.7, Hulsbergen-Van De Kaa C.A.8, Mulders P.F.A.1, Van Oort I.M.1, Van Neste L.10, Schalken J.A.1

Institutes: 1Radboudumc, Dept. of Urology, Nijmegen, The Netherlands, 2ZGT Hospital, Dept. of Urology, Hengelo, The Netherlands, 3Noviogendix, Dept. of Research and Development, Nijmegen, The Netherlands, 4AMC University Medical Centre, Dept. of Urology, Amsterdam, The Netherlands, 5CWZ Hospital, Dept. of Urology, Nijmegen, The Netherlands, 6St Elisabeth Hospital, Dept. of Urology, Tilburg, The Netherlands, 7Scheper Hospital, Dept. of Urology, Emmen, The Netherlands, 8Radboudumc, Dept. of Pathology, Nijmegen, The Netherlands, 9Ghent University, Laboratory of Bioinformatics and Computational Genomics, Ghent, Belgium, 10Maastricht University Medical Center, GROW – School for Oncology and Developmental Biology, Dept. of Pathology, Maastricht, The Netherlands

384
The Prostate Health Index (PHI) predicts positive cancer biopsies in men with a negative mpMRI in a repeat biopsy population

By: Gnanapragasam V.J.1, Burling K.6, George A.1, Kastner C.2, Doble A.2, Barret T.3, Koo B.4, Gallagher F.3, Warren A.5, Ragab M.2

Institutes: 1University of Cambridge, Academic Urology Group, Cambridge, United Kingdom, 2Cambridge University Hospitals NHS Foundation Trust, Dept. of Urology, Cambridge, United Kingdom, 3University of Cambridge, Dept. of Radiology, Cambridge, United Kingdom, 4Cambridge University Hospitals NHS Foundation Trust, Dept. of Radiology, Cambridge, United Kingdom, 5Cambridge University Hospitals NHS Foundation Trust, Dept. of Pathology, Cambridge, United Kingdom, 6Cambridge University Hospitals NHS Foundation Trust, Core Biochemical Assay Laboratory, Cambridge, United Kingdom

385
The ERSPC risk calculator significantly outperforms the PCPT 2.0 in the prediction of prostate cancer: A multi-institutional study

By: Foley R.W.1, Gorman L.2, Murphy K.3, Lundon D.2, Durkan G.4, Power R.5, O’Brien F.6, O’Malley K.J.7, Galvin D.J.8, Murphy B.3, Watson R.W.2

Institutes: 1University College Dublin, UCD School of Medicine, Dublin, Ireland, 2University College Dublin, UCD Conway Institute of Bimolecular and Biomedical Research, Dublin, Ireland, 3University College Dublin, UCD School of Mathematics, Dublin, Ireland, 4University College Galway, Department of Urology, Galway, Ireland, 5Beaumont Hospital, Department of Urology, Dublin, Ireland, 6University Hospital Waterford, Department of Urology, Waterford, Ireland, 7Mater Misericordiae University Hospital, Department of Urology, Dublin, Ireland, 8St. Vincent’s University Hospital, Department of Urology, Dublin, Ireland

386
PCA3 and T2-ERG add further predictive and clinical benefit to the detection of prostate cancer in men of various ages in the early detection research network (EDRN)

By: O’Malley P.1, Golombos D.1, Lewicki P.1, Al Hussein Al Awamlh B.1, Christos P.2, Sanda M.3, Thompson IM4, Wei J.5, Rubin M.6, Barbieri C.1, Scherr D.1

Institutes: 1Weill Cornell Medical College, Dept. of Urology, New York, United States of America, 2Weill Cornell Medical College, Dept. of Healthcare Policy and Research, New York, United States of America, 3Emory University School of Medicine, Dept. of Urology, Atlanta, United States of America, 4University of Texas Health Science Center At San Antonio, Dept. of Urology, San Antonio, United States of America, 5University of Michigan, Dept. of Urology, Ann Arbor, United States of America, 6Weill Cornell Medical College, Dept. of Pathology and Laboratory Medicine, New York, United States of America

387
Identification of population-specific genetic risk profiles in young individuals with or without family history of prostate cancer

By: Cucchiara V.1, Zoccolillo M.2, Vizziello D.3, Lazarevic D.2, Cittaro D.2, Ferrara A.M.1, Gandaglia G.1, Fossati N.1, Benigni F.1, Bianchi M.E.4, Montorsi F.1, Briganti A.1

Institutes: 1IRCCS Ospedale San Raffaele, Dept. of Oncology and Urology, Milan, Italy, 2IRCCS Ospedale San Raffaele, Center For Translational Genomics and BioInformatics, Milan, Italy, 3IRCCS Policlinico San Donato, Dept. of Urology, Milan, Italy, 4IRCCS Ospedale San Raffaele, Dept. of Genetics and Cell Biology, Milan, Italy

388
Genetic variations in the OPG and RANKL genes are associated with prostate cancer risk

By: Ney J.2, Saar M.1, Juhasz-Boess I.2, Assmann G.3, Kasoha M.2, Solomayer E-F.2, Stöckle M.1, Jung V.1

Institutes: 1UKS Universitätsklinikum des Saarlandes, Dept. of Urology & Paediatric, Homburg/Saar, Germany, 2UKS Universitätsklinikum des Saarlandes, Dept. of Gynaecology, Obstetrics and Reproductive Medicine, Homburg/Saar, Germany, 3UKS Universitätsklinikum des Saarlandes, Internal Medicine I, Jose-Carreras-Center For Immuno-and Gene Therapy, Homburg/Saar, Germany

389
Performance of a validated urine-exosome gene signature on initial biopsy in the 4-10ng/mL PSA gray zone: Assessment of avoided biopsies and impact of an adjusted cut-point

By: Donovan M.1, Bentink S.2, Noerholm M.3, O’Neill V.4, Skog J.5

Institutes: 1Icahn School Of Medicine At Mt. Sinai, Dept. of Pathology, New York City, United States of America, 2Exosome Diagnostics GmbH, Dept. of Biostatistics, Martinsreid, Germany, 3Exosome Diagnostics GmbH, Dept. of Product Development, Martinsreid, Germany, 4Exosome Diagnostics, Clinical, Cambridge, United States of America, 5Exosome Diagnostics, Dept. of R&D, Cambridge, United States of America

390
Micromechanical biomarkers are superior to conventional DRE and TRUS biopsy in the detection of prostate cancer

By: Good D.1, Hammer S.2, Scanlan P.2, Stewart G.1, Phipps S.3, Shu W.2, Reuben R.2, McNeill A.3

Institutes: 1University of Edinburgh, Edinburgh Urological Cancer Group, Edinburgh, United Kingdom, 2Heriot Watt University, Dept. of Engineering, Edinburgh, United Kingdom, 3NHS Lothian, Dept. of Urology, Edinburgh, United Kingdom

391
How accurate is the PSA test? A prevalence study of disturbed PSA values in a tertiary referral hospital

By: Poyet C.1, Saba K.1, Lautenbach N.1, Saleh L.2, Umbehr M.3, Sulser T.1, Müntener M.3, Von Eckardstein A.2

Institutes: 1Universitätsspital Zürich, Dept. of Urology, Zürich, Switzerland, 2Universitätsspital Zürich, Institut Für Klinische Chemie, Zürich, Switzerland, 3Stadtspital Triemli Zürich, Dept. of Urology, Zürich, Switzerland

Summary and context
 N. Suardi, Milan (IT)